Infectious Diseases - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/259973

Filters

2021 - 2022 2
2
Reset filters

Settings
Statistics
Citations
Author: Wark, Suzanne × End date: 2022 × Start date: 2020 ×

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Prevalence and Determinants of Vaginal Infection With Human Papillomavirus Among Female University Students in Vietnam
    Van Trang, N ; Prem, K ; Toh, ZQ ; Ha, BTV ; Lan, PTN ; Tran, HP ; Pham, QD ; Van Khuu, N ; Jit, M ; Luu, DT ; Ly, LTK ; Van, C ; Le-Ha, T-D ; Bright, K ; Garland, SM ; Anh, DD ; Mulholland, K (INT INST ANTICANCER RESEARCH, 2022)
    BACKGROUND/AIM: Cervical cancer is the second most common malignancy among women in Vietnam, but the country is yet to introduce a national human papillomavirus (HPV) vaccine programme targeted at adolescents. We determined HPV prevalence and HPV vaccine knowledge among female university students in Vietnam. PATIENTS AND METHODS: We surveyed and screened 1,491 female university students in Hanoi, Hue, and Ho Chi Minh City for their sexual behaviours, HPV knowledge and low- and high-risk HPV infection. RESULTS: The prevalence of any HPV infection and any high-risk HPV infection were 4.2% (95%CI=3.3%-5.4%) and 3.4% (95%CI=2.5%-4.4%), respectively. Being sexually active [adjusted prevalence ratio (aPR): 6.22; 95%CI=3.4-11.37] and having ever been pregnant (aPR: 4.82; 95%CI=1.93-12.04) were positively associated with high-risk HPV infection. Whilst 60% of participants had heard of HPV vaccine, only 4.6% had received the vaccine. CONCLUSION: The low HPV prevalence found in university students in Vietnam indicates that they can benefit from HPV vaccination, along with a well-designed HPV health promotion programme.
  • Item
    No Preview Available
    Evaluation of ResistancePlus MG FleXible, a 'near- patient' test for the detection of Mycoplasma genitalium and macrolide resistance mutations, using freshly collected clinical samples
    Murray, GL ; Doyle, M ; Bodiyabadu, K ; Vodstrcil, LA ; Garland, SM ; Danielewski, J ; Machalek, DA ; McGuinness, C ; Plummer, EL ; De Petra, V ; Williamson, DA ; Bradshaw, CS (MICROBIOLOGY SOC, 2021)
    Introduction. Mycoplasma genitalium is a sexually transmitted pathogen with increasing resistance to first- and second-line antimicrobials. The 'near-patient test' ResistancePlus MG FleXible (SpeeDx) detects M. genitalium plus four macrolide resistance mutations (MRMs), facilitating same-day patient follow up.Hypothesis/Gap Statement. This assay has not been assessed on freshly collected samples.Aim. Our goal was to evaluate the performance of the ResistancePlus MG FleXible test against the standard of care open platform test.Methods. ResistancePlus MG FleXible (analysed on the Cepheid GeneXpert platform) was evaluated on freshly collected samples and compared to the standard of care open platform test ResistancePlus MG (SpeeDx) analysed on the LightCycler 480 II (Roche).Results. For 270 valid tests, ResistancePlus MG FleXible yielded a high positive per cent agreement (PPA) of 94.1% [96/102; 95 % confidence interval (CI): 87.6-97.8 %] and negative per cent agreement (NPA) of 95.2% (160/168; 95 % CI: 90.8-97.9%) for M. genitalium detection compared to the reference assay (kappa for test concordance of 0.89; 95 % CI: 0.83-0.95). Performance was similar across different sample types. For the detection of MRMs, ResistancePlus MG FleXible had a PPA of 97.1% (66/68; 95% CI: 89.8-99.6) and NPA of 78.6% (22/28; 95 % CI: 59.0-91.7), with test comparison kappa of 0.79 (95 % CI: 0.65-0.93). Notably, of six discordant results (i.e. determined to be wild type by the reference assay), five were positive for MRMs by Sanger sequencing, indicating that the ResistancePlus MG FleXible assay has an improved performance for mutation detection.Conclusion. ResistancePlus MG FleXible had comparable test performance for M. genitalium detection as the open platform assay, with improved detection of MRMs. The ResistancePlus MG FleXible 'near-patient' assay can deliver a rapid result to expedite appropriate treatment.